All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On April 2023, the U.S. Food and Drug Administration (FDA) granted fast track designation to CB-011, an allogeneic anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy, for the treatment of relapsed/refractory multiple myeloma.1
CB-011 is a genetically-engineered CAR T cell edited using CRISPR hybrid RNA-DNA.1 These edits include inserting the anti-BCMA CAR into the T cell, removing the beta-2 microglobulin protein, and inserting a beta-2 microglobulin human leukocyte antigen fusion protein.2 The engineering of this therapy aims to improve CAR T-cell persistence and antitumor response through the inhibition of T- and NK-mediated immune rejection.1
CB-011 is currently being evaluated as part of the CaMMouflage phase I trial (NCT05722418). This trial is recruiting patients in the United States who have received at least three prior treatments (including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody) and have not received any previous CAR T-cell therapy. CaMMouflage has two primary outcomes:
What are the main improvements in next-generation CAR T-cell products?
During the 64th ASH Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Benjamin Derman, University of Chicago, Chicago, US. We asked, What are the...
FDA lifts clinical hold on allogeneic CAR T cell therapy trials
On January 10, 2022, the U.S. Food and Drug Administration (FDA) lifted the clinical hold across all trials investigating allogeneic chimeric antigen receptor (allo-CAR) T-cell therapies.
Subscribe to get the best content related to multiple myeloma delivered to your inbox